CPT1A and metabolic dysfunction-associated steatotic liver disease: Both CPT1 and CPT2 are key regulatory enzymes in the regulation of FAO, therefore, enhancing the activity of this pair of isozymes to facilitate fatty acids degradation would be one of the most promising directions for anti-NAFLD drug research and development.